EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Virtual Screening and ADMET Profiling of Natural-Product-Like Compounds as Putative CDK16 Binders

Shafiya Sakina

Clinical & Molecular Biomedicine · 30.09.2026 · 1 (2) · 38

DOI: 10.53295/cmb.v1.i2.100010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Molecular Biomedicine, online erschienen am 30.09.2026. Verfasst von Shafiya Sakina. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin-dependent kinase 16 (CDK16; PCTAIRE1/PCTK1) is an atypical serine/threonine kinase implicated in cellular regulation and cancer biology. This study applied an in-silico workflow to approximately 90,000 natural compounds from the ZINC15 database. Initial physicochemical filtering retained approximately 32,000 compounds for blind molecular docking with InstaDock. The highest-ranked compounds were assessed using predicted ADME/toxicity properties, PAINS filters, solubility-related criteria, and PASS Online activity predictions. Fourteen compounds were retained for detailed profiling, and ZINC04235972 and ZINC02160262 were examined as illustrative docking candidates. Docking poses suggested contacts involving residues around the modeled CDK16 binding region; however, docking scores and predicted contacts do not establish experimental binding or kinase inhibition. Both illustrative compounds had very high predicted drug-induced liver injury (DILI) probabilities (0.996957 and 0.994822), representing substantial predicted liabilities. The docking protocol was not validated by crystallographic-ligand redocking, no biochemical or cellular inhibition data were available, and the screening record did not provide a formal quantitative selection rule or complete comparative ADMET data for all higher-scoring compounds. Accordingly, these compounds should be regarded as unvalidated computational hypotheses, not validated, selective, or therapeutically prioritized CDK16 inhibitors. Experimental testing, chemical-identity confirmation, and complete screening-data reporting are required before further development.

Zitieren

APA

Sakina, S. (2026). Virtual Screening and ADMET Profiling of Natural-Product-Like Compounds as Putative CDK16 Binders. Clinical & Molecular Biomedicine, 1(2), 38. https://doi.org/10.53295/cmb.v1.i2.100010

Vancouver

Sakina S. Virtual Screening and ADMET Profiling of Natural-Product-Like Compounds as Putative CDK16 Binders. Clinical & Molecular Biomedicine. 2026;1(2):38. doi:10.53295/cmb.v1.i2.100010

BibTeX
@article{Sakina2026,
  author = {Sakina, Shafiya},
  title = {Virtual Screening and ADMET Profiling of Natural-Product-Like Compounds as Putative CDK16 Binders},
  journal = {Clinical & Molecular Biomedicine},
  year = {2026},
  volume = {1},
  number = {2},
  pages = {38},
  doi = {10.53295/cmb.v1.i2.100010}
}
Kostenlos starten →